COMMUNIQUÉS West-GlobeNewswire

Hemp Hop Expands Bubble Hash Collection, Positions Format as Quality Benchmark
11/02/2026
CHARLOTTE, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Hemp Hop, a Charlotte-based cannabis brand founded in 2018, announced the February 2026 launch of 3 new THCa Bubble Hash products, expanding its solventless THCa [...]
Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today [...]
iMDx Announces $26.0 Million Registered Direct Offering
11/02/2026
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain [...]
CorVent Medical Completes Common Stock Offering to Support Anticipated Launch of CorVision™ Remote Patient Monitoring (RPM) SaaS Platform
11/02/2026
Proceeds expected to fund company to profitability FARGO, N.D., Feb. 11, 2026 (GLOBE NEWSWIRE) -- CorVent Medical, an innovative medtech company applying artificial intelligence (AI) and machine learning (ML) to improve [...]
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
11/02/2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: [...]
Coloplast A/S - Updated Financial Calendar 2025-26
11/02/2026
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The [...]
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
11/02/2026
• First MYC condensate-modulating small molecule advanced to Development Candidate • Demonstrates potent, selective inhibition of MYC-driven transcription via condensate modulation • Preclinical data support potential [...]
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
11/02/2026
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
PL BioScience Wins Regulatory Certification from Japan’s PMDA
11/02/2026
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has issued a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (GMP Grade) cell culture media. The PMDA Certification is the first regulatory [...]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026
DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces expanded leadership roles [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
NTG Nordic Transport Group A/S - 2025 Annual Report Conference Call
11/02/2026
NTG Nordic Transport Group A/S – 2025 Annual Report Conference Call We expect to release the 2025 Annual Report of NTG Nordic Transport Group on the evening of March 4, 2026. A webcast and conference call will be held [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]

Pages